The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000764336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
27/02/2026
Date registered
Help: Date registered
26/06/2026
Date last updated
Help: Date last updated
26/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
26/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Repeated Low-level Red-Light Therapy in high myopes (8-16 years)
Scientific title
Efficacy of once daily Repeated Low-level Red Light (RLRL) therapy compared to twice daily standard therapy in high myopes: A Non-Inferiority Trial
Additional trial identifiers [1] 316232 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
high myopia 340254 0
Condition category
Condition code
Eye 336449 336449 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Light therapy using a semiconductor laser diode emitting low-level red light at a wavelength of 650 ± 10 nm, with an illuminance of 1600 lux and a light intensity of 0.290 mW.
Intervention: RLRL standard energy emission 3 minutes once daily, 5 days a week for 12 months.
The intervention will be self-administered at home using a handheld device, under the guidance of registered eye care professionals, including optometrists and ophthalmologists.
Patients will be instructed to look inside the target during the treatment period.
The device keeps record of patient usage. When compliance drops below 75%, the system sends reminder message to the patient's parents and eye care professionals. The device also shuts down for 4 hours after the first use to ensure the twice a day administration is at least 4 hours apart.
The family will also have a clinic contact to ensure any concern of device problems can be reported.
Intervention code [1] 332873 0
Treatment: Devices
Description of the comparator or control
Control: RLRL standard energy emission 3 minutes twice a day, 4 hours apart, 5 days a week for 12 months.
Control treatment will be administered at home using handheld devices, under the guidance of registered eye care professionals, including optometrists and ophthalmologists.
Patients will be instructed to look inside the target during the treatment period.
The device keeps record of patient usage. When compliance drops below 75%, the system sends reminder message to the patient's parents and eye care professionals.
Control group
Dose comparison

Outcomes
Primary outcome [1] 343966 0
Axial length of both eyes
Timepoint [1] 343966 0
Baseline (day 0) when the participant starts treatment 1 month post-treatment commencement 3 month post-treatment commencement 6 month post-treatment commencement 9 month post-treatment commencement 12 month post-treatment commencement
Secondary outcome [1] 456261 0
Spherical Equivalent Refraction (cycloplegic refraction) of both eyes
Timepoint [1] 456261 0
Baseline (day 0) when the participant starts treatment 1 month post-treatment commencement 3 month post-treatment commencement 6 month post-treatment commencement 9 month post-treatment commencement 12 month post-treatment commencement
Secondary outcome [2] 456262 0
Subfoveal choroidal thickness of both eyes
Timepoint [2] 456262 0
Baseline (day 0) when the participant starts treatment 1 month post-treatment commencement 3 month post-treatment commencement 6 month post-treatment commencement 9 month post-treatment commencement 12 month post-treatment commencement

Eligibility
Key inclusion criteria
Participants aged 8 to 16 years with high progressive myopia, defined as axial length of 25mm or greater and axial length progression of more than 0.1 mm/6 months on conventional myopic treatment as defined below:
High myopes who are undergoing conventional myopia control treatment, defined as having trialled refractive control, including myopia-control spectacles (e.g. Essilor Stellest or Hoya MiYOSMART) or contact lenses (e.g. CooperVision MiSight), and/or low-dose atropine up to 0.05% concentration, with axial length progression greater than 0.1 mm/6 months.
If participants' myopia treatment includes atropine eye drops, atropine treatment must be ceased, and RLRL started after the pupil becomes reactive, with a maximum diameter of 4 mm, assessed by an Infrared Pupillometer (e.g., NeurOptics NPi-200).
Minimum age
8 Years
Maximum age
16 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants with the following conditions will be excluded from the study:
Manifest deviation (exotropia or esotropia) at near.
Participants with known syndromic myopia, including but not exclusive to Marfan syndrome, Stickler syndrome, retinopathy of prematurity and known retinal dystrophies.
Participants with any systemic diseases that may affect the study, including but not exclusive epilepsy.
Participants wearing orthokeratology as the corneal remodelling from orthokeratology treatment may affect the RLRL therapy, particularly its intensity reaching the eye.


Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The Clinical Trial Coordinator (RA) will not be directly involved in data collection, but will facilitate the trial by performing following tasks (including, but not limited to): allocation of participants to specific trial arms using a centralised electronic randomisation system, and maintenance of the master randomisation list, dispensing of study equipment, implementation of trial procedures and monitoring adherence, recording of adverse events, consultation with investigators regarding the reporting of events to regulatory agencies, reporting actual and potential adverse events, and overseeing and/or coordinating the collection, handling, analysis and reporting of patient and trial data.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
An online block-randomisation technique per recruitment site will be used to allocate participants to either twice-daily or once-daily standard-power devices.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
Questionnaire on outdoor time and near-work activities will be collected via an online questionnaire.
Clinical test data will be saved in the respective equipment and then transferred to a single cloud-based Excel spreadsheet for analysis. Data analysis will be conducted using the Statistical Package for Social Sciences (SPSS) version 29. Outcomes will be analysed using an intention-to-treat approach, with only right eye data included due to high correlation between the two eyes. Based on the normality of the data distribution, for example, continuous variables such as age and AL will be described as means and standard deviations, while categorical variables such as sex will be described as frequencies and percentages.
The treatment effects in all outcomes will be evaluated by calculating the differences before and after treatment (within-subject), and the difference between treatments (between-subjects). Primary and secondary outcomes will be compared between the standard twice daily and once daily RLRL groups using a repeated measures ANOVA incorporating fixed effects for group, visit, treatment group-by-visit interaction. Age, sex and other associated factors such as family history of myopia, outdoor time and near-work activity duration will be adjusted for in the ANOVA analysis. Statistical significance will be set at P <0.05 for the two-tailed tests.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Recruitment postcode(s) [1] 45462 0
2617 - Bruce
Recruitment postcode(s) [2] 45463 0
2109 - Macquarie University
Recruitment postcode(s) [3] 45464 0
4059 - Kelvin Grove
Recruitment postcode(s) [4] 45465 0
5042 - Bedford Park
Recruitment postcode(s) [5] 45466 0
3053 - Carlton

Funding & Sponsors
Funding source category [1] 320834 0
University
Name [1] 320834 0
University of Canberra Researcher Development: Instilling Growth and Nurturing Innovation through Training and Education (ReD IGNITE) program
Country [1] 320834 0
Australia
Funding source category [2] 320835 0
Commercial sector/Industry
Name [2] 320835 0
Eyerising International
Country [2] 320835 0
Australia
Primary sponsor type
University
Name
University of Canberra
Address
Country
Australia
Secondary sponsor category [1] 323507 0
Commercial sector/Industry
Name [1] 323507 0
Eyerising International
Address [1] 323507 0
Country [1] 323507 0
Australia
Other collaborator category [1] 283797 0
University
Name [1] 283797 0
Macquarie University Health- Ophthalmology Clinic
Address [1] 283797 0
Country [1] 283797 0
Australia
Other collaborator category [2] 283798 0
University
Name [2] 283798 0
Queensland University of Technology Health Clinics-Optometry
Address [2] 283798 0
Country [2] 283798 0
Australia
Other collaborator category [3] 283799 0
University
Name [3] 283799 0
Flinders University Health2Go-Optometry
Address [3] 283799 0
Country [3] 283799 0
Australia
Other collaborator category [4] 283800 0
Charities/Societies/Foundations
Name [4] 283800 0
Australian College of Optometry Eye Health Carlton
Address [4] 283800 0
Country [4] 283800 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319366 0
University of Canberra Human Research Ethics Committee
Ethics committee address [1] 319366 0
Ethics committee country [1] 319366 0
Australia
Date submitted for ethics approval [1] 319366 0
16/02/2026
Approval date [1] 319366 0
16/04/2026
Ethics approval number [1] 319366 0
78187

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147102 0
Dr Dinesh Kaphle
Address 147102 0
University of Canberra, 11 Kirinari St Bruce ACT 2617
Country 147102 0
Australia
Phone 147102 0
+61 2 6206 8628
Fax 147102 0
Email 147102 0
Contact person for public queries
Name 147103 0
Dinesh Kaphle
Address 147103 0
University of Canberra, 11 Kirinari St Bruce ACT 2617
Country 147103 0
Australia
Phone 147103 0
+61 2 6206 8628
Fax 147103 0
Email 147103 0
Contact person for scientific queries
Name 147104 0
Dinesh Kaphle
Address 147104 0
University of Canberra, 11 Kirinari St Bruce ACT 2617
Country 147104 0
Australia
Phone 147104 0
+61 2 6206 8628
Fax 147104 0
Email 147104 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After completion of first data analysis
To:
A finite period of: 5 years
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
Yes: University of Canberra Policy on data sharing



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.